The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX expands its clinical-stage pipeline through its proprietary...
This collaboration equips local creative talent with the monetization infrastructure, networks, and market access needed to compete globally. JAKARTA, Indonesia, June 26, 2026...
This collaboration equips local creative talent with the monetization infrastructure, networks, and market access needed to compete globally. JAKARTA, Indonesia, June 26, 2026...